Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab in RVO Macular Edema
NCT00942864Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2008
- Primary completion
- Dec 2009
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in macular edema, sponsored by Novartis. Started Dec 2008; status: completed.
02
Drugs
ranibizumab
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT00942864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00942864.